Latest Observability News

CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.

A landmark High Court ruling in South Africa exempts upstream petroleum activities from the Gas Act, easing regulatory burdens for companies like Renergen and Tetra4.

AUB Group Limited has upgraded its FY25 underlying net profit guidance to the upper end of its previously announced range, buoyed by favourable trading conditions and strategic FX hedging.

Eden Innovations’ US subsidiary has secured its first EdenCrete®Pz7 order from Holcim Mexico, marking the product’s expansion to three countries within the Holcim Group’s concrete operations.

Blue Star Helium has successfully drilled the Jackson 2 well to total depth at its Galactica project in Colorado, confirming strong natural gas flow and advancing the project toward commercial production.

Kip McGrath Education Centres announces the departure of long-serving CEO Storm McGrath, with Chair Damian Banks stepping in as Executive Chair during the leadership transition.

Pact Group Holdings has received conditional approval from the ASX for its voluntary delisting, pending shareholder endorsement at an upcoming extraordinary general meeting scheduled for 12 June 2025.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Stellar Resources reports strong high-grade tin intercepts at Queen Hill, underpinning potential resource upgrades and advancing the Heemskirk Tin Project towards development.

Enlitic has formalised a binding MOU with GE HealthCare to deliver multi-million-dollar migration services, contingent on raising A$10 million through a new capital placement. This partnership and funding round mark a pivotal step in Enlitic’s growth strategy within AI-driven medical imaging.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.